Devin W Kehl, MD
Cardiovascular Disease (Cardiology) · Santa Monica
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Cedars-Sinai Medical Care Foundation · 1,684 clinicians in this group
Hospitals listed: Cedars-Sinai Medical Center · Saint John'S Health Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kehl’s office at (310) 582-7900 to ask if they take your plan before you enroll.
California Medical Board record
Licence A118294 · Current
Licensed to practise in California · since 2011 · expires 2027-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Cedars-Sinai Medical CenterLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Postoperative sepsis rate: 7.77 (6.11 to 9.44) · 6,132 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.2 to 14.7) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 134.15 (109.33 to 158.98) · 557 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.386, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.661, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.628, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.503, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.8 (3 to 4.8) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.8) · 2,580 cases, Jan 2024 – Dec 2024
- Saint John'S Health CenterSanta Monica, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — SSI - Colon Surgery: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Cedars-Sinai Medical Center
Behind the star rating — Deaths: 7 better, 1 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 7.77 (6.11 to 9.44) · 6,132 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.2 to 14.7) · 1,174 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.15 (109.33 to 158.98) · 557 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.386 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.661 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.628 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.503 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.8 (3 to 4.8) · 1,174 cases | Better | Jan 2024 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.8) · 2,580 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.66 (0.06 to 1.25) · 8,257 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.92 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 223 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.9 · 191 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.3 · 409 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.5 · 1,544 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.5 · 1,742 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 549 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.3 · 9,504 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.28) · 29,170 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.05 to 0.32) · 31,661 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.1 (3.06 to 5.14) · 11,199 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0.47 to 2.29) · 6,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (1.24 to 2.86) · 10,075 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.2 (5.76 to 10.65) · 6,012 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.91 (0.72 to 3.11) · 2,803 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.75 (0.47 to 1.03) · 27,865 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 472 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.437 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.168 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 492 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 1,750 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.9 · 498 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5.8 · 1,908 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.7 · 1,850 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 1,572 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.7 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 172 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 240 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.1 to 17.5) · 1,197 cases | No different | Jan 2022 – Dec 2024 |
What patients said (1,081 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Saint John'S Health Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.64 (0 to 1.49) · 1,939 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.6 to 1.12) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 140.49 (93.64 to 187.34) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 33 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.7 · 101 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 412 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11 · 615 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 317 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,461 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.03 to 0.42) · 8,758 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.18 (0 to 0.36) · 9,150 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.57 (0.92 to 4.22) · 3,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.03 to 3.91) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.39 to 3) · 3,369 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.55 (3.36 to 13.74) · 2,341 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.38 (3.53 to 9.24) · 2,433 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.52 (0.1 to 2.94) · 677 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.25 (0 to 0.81) · 6,775 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.3 · 945 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.631 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.6 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.069 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.268 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14 · 174 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.3 · 178 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.3 · 458 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.4 · 646 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 605 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3.1 to 6.8) · 246 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.6 (7.7 to 14.4) · 246 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 3.5 · 907 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9 to 15.8) · 258 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 955 cases | No different | Jan 2024 – Dec 2024 |
What patients said (450 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 78% |
| Yes, staff "did" give patients information about help after discharge | 77% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 77% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 79% |
Original Medicare doctor bills
$482,416
Medicare paid this office $482,416 for 1,438 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, inclisiran, 1 mg | 32 | $159,159 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 594 | $103,146 | $165 |
| Long return visit (40+ min) | 157 | $40,660 | $151 |
| Return visit (30+ min) | 275 | $36,968 | $97 |
| New patient visit (60+ min) | 118 | $19,171 | $162 |
See all 37 services
| Injection, inclisiran, 1 mg | 32 | $159,159 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 594 | $103,146 | $165 |
| Long return visit (40+ min) | 157 | $40,660 | $151 |
| Return visit (30+ min) | 275 | $36,968 | $97 |
| New patient visit (60+ min) | 118 | $19,171 | $162 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 315 | $17,943 | $54 |
| Heart muscle strain imaging | 452 | $15,425 | $33 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 67 | $13,069 | $195 |
| New patient visit (45+ min) | 72 | $9,111 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $8,749 | $137 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 382 | $8,710 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $7,801 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 61 | $7,443 | $65 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 91 | $4,626 | $50 |
| Ultrasound of heart with probe in esophagus, with report | 44 | $4,091 | $85 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 278 | $3,854 | $12 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 17 | $3,111 | $183 |
| Short return visit (20+ min) | 41 | $2,596 | $59 |
| Ultrasound of heart blood flow, valves and chambers | 50 | $2,292 | $46 |
| External shock to heart to regulate heart beat | 16 | $1,524 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 61 | $1,321 | $22 |
| Ultrasound of heart, follow-up | 11 | $992 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 15 | $926 | $58 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $866 | $67 |
| Injection of drug or substance under skin or into muscle | 32 | $745 | $13 |
| Ultrasound of heart, follow-up | 32 | $675 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 42 | $658 | $15 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 32 | $651 | $20 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 30 | $590 | $19 |
| Insertion of needle into vein for collection of blood sample | 47 | $519 | $9 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 65 | $474 | $6 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 29 | $331 | $11 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $295 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 27 | $295 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 56 | $153 | $3 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 18 | $121 | $7 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 20 | $117 | $6 |
Procedures Medicare counted
| Laminectomy or laminotomy (partial removal of spine bones) | 1-10 | None |
Who their Medicare patients are
1,438 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 26% · Women 50% · Also on Medicaid 13% · Health risk score 1.57. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 59% · Atrial fibrillation 40% · Heart failure 34% · Diabetes 29% · Chronic kidney disease 28% · Depression 23% · Cancer 21% · COPD 16% · Stroke 16% · Dementia 12%.
The office billed $2,539,344, Medicare allowed $632,291 and paid $482,416; for 21,261 services of 50 kinds; $159,444 of it was for drugs given in the office and $322,972 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,438 | 21,261 | 79 | 1.57 | $2,539,344 | $482,416 |
| 2023 | 1,246 | 12,940 | 79 | 1.63 | $1,873,974 | $356,826 |
| 2022 | 1,143 | 2,928 | 79 | 1.60 | $1,457,528 | $253,374 |
| 2021 | 1,596 | 8,651 | 77 | 1.16 | $1,111,675 | $249,877 |
| 2020 | 1,476 | 4,733 | 77 | 1.19 | $796,253 | $188,303 |
| 2019 | 1,705 | 3,013 | 78 | 1.24 | $848,084 | $217,702 |
| 2018 | 1,446 | 2,465 | 77 | 1.21 | $728,441 | $190,009 |
| 2017 | 409 | 595 | 78 | 1.23 | $133,592 | $39,721 |
| 2014 | 32 | 60 | 74 | 2.58 | $19,940 | $6,582 |
| 2013 | 11 | 15 | 67 | 3.54 | $4,899 | $1,529 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 34 services
| Injection, inclisiran, 1 mg | 24 | $91,055 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 449 | $81,333 | $174 |
| Return visit (30+ min) | 219 | $35,355 | $104 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 351 | $21,263 | $58 |
| New patient visit (60+ min) | 100 | $18,098 | $181 |
| Long return visit (40+ min) | 85 | $17,769 | $148 |
| Heart muscle strain imaging | 331 | $11,729 | $35 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 55 | $11,071 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $10,644 | $65 |
| New patient visit (45+ min) | 70 | $9,233 | $132 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $6,680 | $145 |
| Short return visit (20+ min) | 65 | $4,683 | $64 |
| Ultrasound of heart with probe in esophagus, with report | 40 | $3,903 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,640 | $98 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 63 | $3,168 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 225 | $3,091 | $12 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $2,882 | $103 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | $2,576 | $78 |
| Ultrasound of heart blood flow, valves and chambers | 43 | $1,993 | $46 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,742 | $109 |
| External shock to heart to regulate heart beat | 13 | $1,302 | $93 |
| Ultrasound of heart, follow-up | 13 | $1,199 | $92 |
| Insertion of needle into vein for collection of blood sample | 102 | $991 | $8 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 45 | $991 | $22 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 36 | $703 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 40 | $653 | $15 |
| Ultrasound of heart, follow-up | 26 | $595 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 50 | $466 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 20 | $443 | $22 |
| Injection of drug or substance under skin or into muscle | 24 | $434 | $13 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 34 | $395 | $12 |
| Heart rhythm recording of continous external ekg over 8-15 days | 18 | $207 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 40 | $110 | $3 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 11 | $66 | $6 |
2022: 31 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 411 | $72,570 | $173 |
| Long return visit (40+ min) | 91 | $21,267 | $154 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 305 | $19,000 | $60 |
| New patient visit (60+ min) | 106 | $18,422 | $174 |
| Return visit (30+ min) | 104 | $16,973 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $15,823 | $85 |
| New patient visit (45+ min) | 94 | $12,613 | $134 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 64 | $12,270 | $192 |
| Heart muscle strain imaging | 311 | $11,192 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $5,871 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $5,626 | $156 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $4,989 | $116 |
| Ultrasound of heart with probe in esophagus, with report | 47 | $4,678 | $94 |
| Ultrasound of heart blood flow, valves and chambers | 62 | $2,965 | $48 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $2,897 | $116 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 56 | $2,788 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 183 | $2,597 | $12 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 13 | $2,553 | $196 |
| New patient visit (60+ min) | 15 | $2,283 | $152 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $1,711 | $81 |
| Short return visit (20+ min) | 19 | $1,619 | $81 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 63 | $1,440 | $23 |
| Ultrasound of heart, follow-up | 34 | $771 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 46 | $762 | $16 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 21 | $444 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 52 | $418 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 13 | $304 | $23 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 18 | $237 | $13 |
| Heart rhythm recording of continous external ekg over 8-15 days | 14 | $184 | $13 |
| Insertion of needle into vein for collection of blood sample | 53 | $183 | $3 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 47 | $138 | $3 |
2021: 24 services
| Return visit (30+ min) | 341 | $69,102 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 178 | $37,040 | $207 |
| Long return visit (40+ min) | 111 | $23,221 | $164 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 94 | $23,055 | $245 |
| Ct scan of blood vessels and grafts of heart with contrast | 73 | $22,013 | $302 |
| Short return visit (20+ min) | 107 | $10,512 | $81 |
| New patient visit (45+ min) | 58 | $8,535 | $147 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 51 | $8,475 | $163 |
| Ct scan of heart with evaluation of blood vessel calcium | 56 | $5,532 | $99 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 393 | $5,445 | $13 |
| New patient visit (60+ min) | 25 | $4,811 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $4,689 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $4,226 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,755 | $94 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 230 | $2,265 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 71 | $1,784 | $25 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $1,780 | $68 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 63 | $1,695 | $20 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,501 | $88 |
| Heart rhythm recording of continous external ekg over 8-15 days | 66 | $1,078 | $16 |
| Heart muscle strain imaging | 17 | $738 | $43 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 69 | $548 | $0 |
| 3d radiographic procedure | 20 | $470 | $24 |
| Blood test, clotting time | 65 | $438 | $4 |
2020: 29 services
| Return visit (30+ min) | 308 | $49,306 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 167 | $32,515 | $195 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 82 | $18,612 | $227 |
| New patient visit (45+ min) | 68 | $9,532 | $140 |
| Ct scan of blood vessels and grafts of heart with contrast | 28 | $8,832 | $315 |
| Long return visit (40+ min) | 48 | $8,413 | $127 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 420 | $6,306 | $15 |
| Telephone medical discussion with physician, 21-30 minutes | 42 | $5,886 | $105 |
| Short return visit (20+ min) | 69 | $5,000 | $66 |
| Telephone medical discussion with physician, 11-20 minutes | 51 | $4,588 | $73 |
| New patient visit (60+ min) | 23 | $4,220 | $183 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,867 | $125 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,589 | $68 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 14 | $2,970 | $212 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 89 | $2,296 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 232 | $2,089 | $7 |
| External ekg recording for more than 48 hours up to 21 days | 69 | $2,027 | $29 |
| Ct scan of heart with evaluation of blood vessel calcium | 18 | $2,023 | $112 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 62 | $2,005 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,747 | $97 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,225 | $94 |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 17 | $962 | $48 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $709 | $27 |
| Blood test, clotting time | 87 | $645 | $4 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $509 | $36 |
| High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 23 | $255 | $0 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $223 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $198 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 13 | $39 | $3 |
2019: 27 services
| Return visit (30+ min) | 349 | $66,383 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 218 | $43,073 | $195 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 111 | $25,523 | $230 |
| Long return visit (40+ min) | 86 | $13,675 | $129 |
| New patient visit (45+ min) | 82 | $11,561 | $141 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 559 | $8,410 | $15 |
| New patient visit (60+ min) | 38 | $6,772 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $4,772 | $64 |
| Short return visit (20+ min) | 50 | $3,901 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,230 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,652 | $95 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 90 | $2,606 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 85 | $2,335 | $27 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,314 | $178 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $2,310 | $210 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 11 | $2,299 | $209 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 85 | $2,052 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 23 | $1,797 | $75 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 188 | $1,725 | $8 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,301 | $100 |
| Blood test, clotting time | 115 | $837 | $4 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 19 | $491 | $26 |
| Ultrasound of heart blood flow, valves and chambers | 22 | $371 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 17 | $234 | $14 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $188 | $11 |
| 3d radiographic procedure | 18 | $162 | $9 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 22 | $65 | $3 |
2018: 26 services
| Return visit (30+ min) | 252 | $48,507 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 196 | $41,322 | $208 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 78 | $17,169 | $220 |
| New patient visit (45+ min) | 97 | $13,552 | $140 |
| Long return visit (40+ min) | 68 | $10,444 | $132 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 528 | $8,119 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $7,844 | $65 |
| Extended office or other outpatient service, first hour | 47 | $4,657 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,644 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,220 | $179 |
| New patient visit (60+ min) | 17 | $3,027 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,715 | $94 |
| Short return visit (20+ min) | 44 | $2,714 | $60 |
| Ultrasound of heart with probe in esophagus, with report | 26 | $2,540 | $94 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $2,481 | $207 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 26 | $2,076 | $80 |
| External ekg recording for more than 48 hours up to 21 days | 72 | $1,977 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 71 | $1,739 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 157 | $1,305 | $7 |
| New patient visit (30+ min) | 11 | $868 | $79 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 14 | $867 | $62 |
| Ultrasound of heart blood flow, valves and chambers | 32 | $565 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 26 | $350 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $331 | $25 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 32 | $98 | $3 |
| 3d radiographic procedure | 11 | $97 | $9 |
2017: 10 services
| Return visit (30+ min) | 120 | $14,480 | $101 |
| New patient visit (45+ min) | 36 | $5,426 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $3,628 | $65 |
| Long return visit (40+ min) | 21 | $2,840 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,357 | $181 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,709 | $114 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 95 | $1,522 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 95 | $880 | $8 |
| External ekg recording for more than 48 hours up to 21 days | 15 | $419 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 15 | $365 | $24 |
2014: 1 service
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,314 | $154 |
Medicaid work
$1,156 in 2024
Medicaid paid $1,156 for 29 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 29 | $1,156 |
| 2024 | 29 | 1 | 16 | $1,156 |
| 2023 | 79 | 1 | 19 | $2,887 |
| 2022 | 41 | 1 | 17 | $2,268 |
| 2021 | 113 | 1 | 63 | $982 |
| 2020 | 76 | 2 | 26 | $923 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 79 | $2,887 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 41 | $2,268 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 113 | $982 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 61 | $722 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 15 | $200 |
Drugs they prescribed that Part D paid
$1,108,143
Pharmacies billed $1,108,143 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
3,248 generic and fewer than 11 brand-name prescriptions · $1,108,143 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 242 | $274,208 | $1,133 |
| Repatha Sureclick | 240 | $261,469 | $1,089 |
| Jardiance | 127 | $167,852 | $1,322 |
| Entresto | 108 | $122,570 | $1,135 |
| Farxiga | 59 | $59,731 | $1,012 |
See all 41 drugs
| Eliquis | 242 | $274,208 | $1,133 |
| Repatha Sureclick | 240 | $261,469 | $1,089 |
| Jardiance | 127 | $167,852 | $1,322 |
| Entresto | 108 | $122,570 | $1,135 |
| Farxiga | 59 | $59,731 | $1,012 |
| Praluent | 62 | $45,411 | $732 |
| Xarelto | 35 | $37,193 | $1,063 |
| Mounjaro | 16 | $16,224 | $1,014 |
| Rosuvastatin | 557 | $9,946 | $18 |
| Ezetimibe | 166 | $6,229 | $38 |
| Atorvastatin | 466 | $5,764 | $12 |
| Metoprolol | 292 | $5,000 | $17 |
| Amiodarone | 32 | $3,331 | $104 |
| Valsartan | 111 | $3,276 | $30 |
| Olmesartan Medoxomil | 99 | $2,760 | $28 |
| Amlodipine Besylate | 255 | $1,995 | $8 |
| Telmisartan | 51 | $1,943 | $38 |
| Losartan | 136 | $1,610 | $12 |
| Diltiazem 24hr Er (Cd) | 24 | $1,303 | $54 |
| Potassium Chloride | 17 | $1,164 | $68 |
| Bumetanide | 17 | $974 | $57 |
| Chlorthalidone | 41 | $903 | $22 |
| Carvedilol | 108 | $859 | $8 |
| Colchicine | 11 | $846 | $77 |
| Hydralazine | 52 | $745 | $14 |
| Furosemide | 162 | $741 | $5 |
| Irbesartan | 39 | $713 | $18 |
| Metoprolol | 76 | $691 | $9 |
| Nifedipine Er | 13 | $643 | $49 |
| Lisinopril | 74 | $575 | $8 |
| Clopidogrel | 44 | $531 | $12 |
| Spironolactone | 63 | $427 | $7 |
| Eplerenone | 12 | $382 | $32 |
| Nitroglycerin | 18 | $357 | $20 |
| Metformin | 13 | $305 | $23 |
| Enalapril Maleate | 14 | $300 | $21 |
| Diltiazem 24hr Er (Xr) | 11 | $258 | $23 |
| Hydrochlorothiazide | 35 | $226 | $6 |
| Pravastatin | 14 | $153 | $11 |
| Losartan-Hydrochlorothiazide | 11 | $139 | $13 |
| Digoxin | 13 | $104 | $8 |
Year by year
| 2024 | 4,237 | 641 | None | None | $1,108,143 |
| 2023 | 2,811 | 452 | 0% (0) | None | $674,801 |
| 2022 | 2,751 | 664 | 0% (0) | None | $632,622 |
| 2021 | 4,509 | 590 | 0% (0) | None | $877,404 |
| 2020 | 3,915 | 508 | 0% (0) | 15% | $548,600 |
| 2019 | 3,163 | 440 | 0% (0) | 14% | $368,797 |
| 2018 | 1,973 | 329 | 0% (0) | 13% | $164,935 |
| 2017 | 400 | 138 | 0% (0) | 22% | $19,050 |
| 2016 | 127 | 41 | 0% (0) | 25% | $4,112 |
| 2015 | 134 | 21 | 0% (0) | 20% | $5,757 |
| 2014 | 56 | 13 | None | None | $2,672 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Eliquis | 149 | $189,558 | $1,272 |
| Jardiance | 65 | $96,817 | $1,489 |
| Repatha Sureclick | 96 | $86,119 | $897 |
| Entresto | 69 | $79,183 | $1,148 |
| Praluent | 68 | $56,254 | $827 |
| Farxiga | 34 | $43,705 | $1,285 |
| Rosuvastatin | 406 | $18,165 | $45 |
| Ezetimibe | 84 | $5,963 | $71 |
| Olmesartan Medoxomil | 68 | $5,715 | $84 |
| Atorvastatin | 323 | $5,526 | $17 |
| Metoprolol | 171 | $4,276 | $25 |
| Diltiazem 24hr Er (Cd) | 28 | $4,020 | $144 |
| Amiodarone | 20 | $3,788 | $189 |
| Valsartan | 62 | $2,644 | $43 |
| Amlodipine Besylate | 158 | $1,625 | $10 |
| Losartan | 100 | $1,577 | $16 |
| Telmisartan | 17 | $1,324 | $78 |
| Torsemide | 19 | $1,270 | $67 |
| Eplerenone | 15 | $1,192 | $79 |
| Hydralazine | 51 | $1,156 | $23 |
| Irbesartan | 30 | $1,074 | $36 |
| Carvedilol | 74 | $1,070 | $14 |
| Nitroglycerin | 34 | $1,030 | $30 |
| Bumetanide | 14 | $1,022 | $73 |
| Furosemide | 109 | $836 | $8 |
| Lisinopril | 68 | $814 | $12 |
| Metoprolol | 74 | $783 | $11 |
| Chlorthalidone | 22 | $705 | $32 |
| Spironolactone | 38 | $685 | $18 |
| Potassium Chloride | 17 | $474 | $28 |
| Clopidogrel | 30 | $453 | $15 |
| Flecainide Acetate | 12 | $376 | $31 |
| Losartan-Hydrochlorothiazide | 11 | $359 | $33 |
| Valsartan-Hydrochlorothiazide | 14 | $265 | $19 |
| Hydrochlorothiazide | 33 | $262 | $8 |
2022: 33 drugs
| Eliquis | 180 | $216,758 | $1,204 |
| Entresto | 38 | $48,943 | $1,288 |
| Repatha Sureclick | 52 | $30,345 | $584 |
| Praluent | 51 | $29,543 | $579 |
| Farxiga | 14 | $19,417 | $1,387 |
| Rosuvastatin | 317 | $16,461 | $52 |
| Ezetimibe | 111 | $7,480 | $67 |
| Metoprolol | 219 | $5,438 | $25 |
| Atorvastatin | 390 | $5,226 | $13 |
| Diltiazem 24hr Er (Cd) | 47 | $4,233 | $90 |
| Losartan | 186 | $2,502 | $13 |
| Valsartan | 29 | $1,958 | $68 |
| Bumetanide | 23 | $1,882 | $82 |
| Olmesartan Medoxomil | 24 | $1,513 | $63 |
| Carvedilol | 71 | $1,257 | $18 |
| Amlodipine Besylate | 147 | $1,139 | $8 |
| Lisinopril | 109 | $1,099 | $10 |
| Furosemide | 130 | $922 | $7 |
| Isosorbide Mononitrate Er | 28 | $831 | $30 |
| Nitroglycerin | 36 | $819 | $23 |
| Potassium Chloride | 16 | $795 | $50 |
| Hydralazine | 23 | $659 | $29 |
| Chlorthalidone | 17 | $566 | $33 |
| Spironolactone | 40 | $560 | $14 |
| Amiodarone | 18 | $538 | $30 |
| Pravastatin | 36 | $526 | $15 |
| Irbesartan | 17 | $508 | $30 |
| Warfarin | 16 | $451 | $28 |
| Hydrochlorothiazide | 49 | $450 | $9 |
| Metoprolol | 50 | $449 | $9 |
| Clopidogrel | 28 | $370 | $13 |
| Losartan-Hydrochlorothiazide | 12 | $236 | $20 |
| Atenolol | 21 | $188 | $9 |
2021: 41 drugs
| Eliquis | 310 | $359,356 | $1,159 |
| Vyndamax | 12 | $220,734 | $18,395 |
| Praluent | 94 | $52,361 | $557 |
| Xarelto | 49 | $48,228 | $984 |
| Entresto | 30 | $43,334 | $1,444 |
| Repatha Sureclick | 39 | $19,271 | $494 |
| Rosuvastatin | 369 | $15,516 | $42 |
| Brilinta | 19 | $14,359 | $756 |
| Atorvastatin | 694 | $10,740 | $15 |
| Metoprolol | 408 | $9,784 | $24 |
| Ezetimibe | 145 | $9,778 | $67 |
| Losartan | 322 | $5,245 | $16 |
| Potassium Chloride | 58 | $4,120 | $71 |
| Valsartan | 62 | $3,754 | $61 |
| Bumetanide | 32 | $3,712 | $116 |
| Amlodipine Besylate | 297 | $2,888 | $10 |
| Isosorbide Mononitrate Er | 56 | $2,145 | $38 |
| Carvedilol | 129 | $2,143 | $17 |
| Lisinopril | 203 | $2,032 | $10 |
| Amiodarone | 25 | $1,990 | $80 |
| Furosemide | 204 | $1,847 | $9 |
| Diltiazem 24hr Er (Cd) | 40 | $1,833 | $46 |
| Nitroglycerin | 33 | $1,372 | $42 |
| Irbesartan | 24 | $1,283 | $53 |
| Chlorthalidone | 29 | $1,238 | $43 |
| Pravastatin | 63 | $1,218 | $19 |
| Metoprolol | 128 | $999 | $8 |
| Hydrochlorothiazide | 100 | $933 | $9 |
| Warfarin | 45 | $882 | $20 |
| Hydralazine | 32 | $829 | $26 |
| Atenolol | 56 | $799 | $14 |
| Spironolactone | 62 | $735 | $12 |
| Clopidogrel | 31 | $691 | $22 |
| Spironolactone-Hctz | 11 | $453 | $41 |
| Triamterene-Hydrochlorothiazid | 23 | $376 | $16 |
| Simvastatin | 36 | $313 | $9 |
| Losartan-Hydrochlorothiazide | 13 | $200 | $15 |
| Benazepril | 11 | $146 | $13 |
| Labetalol | 12 | $144 | $12 |
| Lisinopril-Hydrochlorothiazide | 16 | $136 | $8 |
| Amoxicillin | 16 | $17 | $1 |
2020: 37 drugs
| Eliquis | 255 | $280,367 | $1,099 |
| Praluent | 90 | $48,508 | $539 |
| Xarelto | 43 | $42,369 | $985 |
| Rosuvastatin | 308 | $17,350 | $56 |
| Atorvastatin | 570 | $11,562 | $20 |
| Metoprolol | 410 | $11,047 | $27 |
| Ezetimibe | 96 | $7,245 | $75 |
| Losartan | 278 | $4,092 | $15 |
| Valsartan | 49 | $3,867 | $79 |
| Amiodarone | 23 | $2,970 | $129 |
| Amlodipine Besylate | 278 | $2,596 | $9 |
| Potassium Chloride | 47 | $2,472 | $53 |
| Bumetanide | 19 | $2,165 | $114 |
| Lisinopril | 195 | $2,057 | $11 |
| Furosemide | 186 | $1,725 | $9 |
| Carvedilol | 110 | $1,700 | $15 |
| Diltiazem 24hr Er (Cd) | 43 | $1,658 | $39 |
| Warfarin | 59 | $1,426 | $24 |
| Dilt-Xr | 14 | $1,318 | $94 |
| Pravastatin | 59 | $1,302 | $22 |
| Losartan-Hydrochlorothiazide | 14 | $1,289 | $92 |
| Clopidogrel | 45 | $1,095 | $24 |
| Isosorbide Mononitrate Er | 41 | $1,057 | $26 |
| Irbesartan | 17 | $1,048 | $62 |
| Nitroglycerin | 34 | $992 | $29 |
| Chlorthalidone | 24 | $925 | $39 |
| Hydrochlorothiazide | 103 | $882 | $9 |
| Metoprolol | 95 | $762 | $8 |
| Atenolol | 61 | $725 | $12 |
| Hydralazine | 28 | $510 | $18 |
| Spironolactone | 39 | $487 | $12 |
| Simvastatin | 45 | $416 | $9 |
| Spironolactone-Hctz | 11 | $382 | $35 |
| Labetalol | 15 | $230 | $15 |
| Triamterene-Hydrochlorothiazid | 11 | $221 | $20 |
| Lisinopril-Hydrochlorothiazide | 17 | $214 | $13 |
| Amoxicillin | 21 | $34 | $2 |
2019: 35 drugs
| Eliquis | 170 | $183,188 | $1,078 |
| Praluent | 72 | $52,134 | $724 |
| Xarelto | 41 | $45,713 | $1,115 |
| Rosuvastatin | 203 | $14,170 | $70 |
| Atorvastatin | 492 | $10,948 | $22 |
| Metoprolol | 326 | $10,223 | $31 |
| Ezetimibe | 52 | $3,462 | $67 |
| Losartan | 236 | $3,084 | $13 |
| Potassium Chloride | 45 | $2,326 | $52 |
| Carvedilol | 141 | $2,164 | $15 |
| Lisinopril | 186 | $1,897 | $10 |
| Amlodipine Besylate | 216 | $1,861 | $9 |
| Bumetanide | 16 | $1,846 | $115 |
| Isosorbide Mononitrate Er | 35 | $1,536 | $44 |
| Warfarin | 45 | $1,291 | $29 |
| Pravastatin | 56 | $1,288 | $23 |
| Amiodarone | 17 | $1,184 | $70 |
| Furosemide | 147 | $1,132 | $8 |
| Dilt-Xr | 14 | $1,110 | $79 |
| Valsartan | 22 | $1,083 | $49 |
| Clopidogrel | 46 | $1,017 | $22 |
| Irbesartan | 17 | $992 | $58 |
| Diltiazem 24hr Er (Cd) | 37 | $972 | $26 |
| Nitroglycerin | 45 | $843 | $19 |
| Hydralazine | 24 | $733 | $31 |
| Chlorthalidone | 16 | $695 | $43 |
| Hydrochlorothiazide | 79 | $629 | $8 |
| Metoprolol | 56 | $625 | $11 |
| Atenolol | 47 | $546 | $12 |
| Cartia Xt | 14 | $486 | $35 |
| Doxazosin Mesylate | 12 | $411 | $34 |
| Spironolactone | 23 | $251 | $11 |
| Labetalol | 12 | $235 | $20 |
| Simvastatin | 32 | $220 | $7 |
| Valsartan-Hydrochlorothiazide | 12 | $208 | $17 |
2018: 24 drugs
| Eliquis | 101 | $89,007 | $881 |
| Xarelto | 22 | $15,128 | $688 |
| Metoprolol | 223 | $8,668 | $39 |
| Atorvastatin | 270 | $7,374 | $27 |
| Rosuvastatin | 83 | $4,662 | $56 |
| Isosorbide Mononitrate Er | 44 | $1,682 | $38 |
| Potassium Chloride | 33 | $1,500 | $45 |
| Carvedilol | 118 | $1,434 | $12 |
| Pravastatin | 55 | $1,346 | $24 |
| Lisinopril | 132 | $1,224 | $9 |
| Amlodipine Besylate | 140 | $1,183 | $8 |
| Losartan | 116 | $1,141 | $10 |
| Furosemide | 113 | $990 | $9 |
| Warfarin | 25 | $977 | $39 |
| Valsartan | 22 | $786 | $36 |
| Nitroglycerin | 38 | $611 | $16 |
| Clopidogrel | 23 | $550 | $24 |
| Atenolol | 37 | $456 | $12 |
| Simvastatin | 46 | $365 | $8 |
| Metoprolol | 48 | $317 | $7 |
| Diltiazem 24hr Er (Cd) | 15 | $315 | $21 |
| Hydrochlorothiazide | 47 | $245 | $5 |
| Spironolactone | 20 | $229 | $11 |
| Valsartan-Hydrochlorothiazide | 12 | $90 | $8 |
2017: 13 drugs
| Atorvastatin | 46 | $1,325 | $29 |
| Metoprolol | 34 | $1,134 | $33 |
| Isosorbide Mononitrate Er | 26 | $483 | $19 |
| Metoprolol | 42 | $377 | $9 |
| Bisoprolol | 12 | $376 | $31 |
| Losartan | 19 | $371 | $20 |
| Nitroglycerin | 12 | $328 | $27 |
| Furosemide | 30 | $245 | $8 |
| Lisinopril | 21 | $226 | $11 |
| Carvedilol | 22 | $220 | $10 |
| Pravastatin | 14 | $211 | $15 |
| Warfarin | 13 | $197 | $15 |
| Amlodipine Besylate | 30 | $190 | $6 |
2016: 4 drugs
| Atorvastatin | 15 | $556 | $37 |
| Bisoprolol | 11 | $488 | $44 |
| Metoprolol | 29 | $235 | $8 |
| Lisinopril | 15 | $164 | $11 |
2015: 4 drugs
| Atorvastatin | 16 | $353 | $22 |
| Lisinopril | 23 | $215 | $9 |
| Metoprolol | 17 | $151 | $9 |
| Clopidogrel | 13 | $80 | $6 |
Money from drug and device companies
$970 in 2025
| 2025 | 11 | 58 | None | $970 |
| 2024 | 13 | 66 | None | $991 |
| 2023 | 13 | 20 | None | $535 |
| 2022 | 4 | 6 | None | $164 |
| 2020 | 1 | 10 | None | $1,196 |
| 2019 | 1 | 19 | None | $3,089 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Leqvio | $412 | 24 payments
|
| Amgen | Repatha | $160 | 16 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $121 | 6 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $96 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $50 | 2 payments
|
| Inspire Medical Systems | Inspire | $33 | 1 payment
|
See all 58 published payments
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-18 | Camzyos | $26 |
| Amgen | Meals · 2025-12-18 | Repatha | $29 |
| Novartis Pharmaceuticals | Meals · 2025-12-16 | Leqvio | $30 |
| Amgen | Meals · 2025-12-15 | Repatha | $6 |
| Amgen | Meals · 2025-11-21 | Repatha | $3 |
| Alnylam Pharmaceuticals | Meals · 2025-11-20 | Amvuttra | $24 |
| Pfizer | Meals · 2025-11-11 | Vyndaqel | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-05 | Eliquis | $17 |
| Esperion Therapeutics | Meals · 2025-10-30 | Nexletol | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-23 | Camzyos | $23 |
| Amgen | Meals · 2025-10-17 | Repatha | $8 |
| Novartis Pharmaceuticals | Meals · 2025-10-16 | Leqvio | $25 |
| Inspire Medical Systems | Meals · 2025-10-14 | Inspire | $33 |
| Baxter Healthcare | Meals · 2025-10-02 | Hillrom - Cardiac Ambulatory Monitor | $16 |
| Amgen | Meals · 2025-09-30 | Repatha | $8 |
| Kestra Medical Technology Services | Meals · 2025-09-26 | Assure Wcd | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-18 | Leqvio | $3 |
| Novartis Pharmaceuticals | Meals · 2025-09-18 | Leqvio | $24 |
| Amgen | Meals · 2025-09-18 | Repatha | $9 |
| Amgen | Meals · 2025-09-11 | Repatha | $25 |
| Amgen | Meals · 2025-09-10 | Repatha | $6 |
| Novartis Pharmaceuticals | Meals · 2025-08-28 | Leqvio | $18 |
| Novartis Pharmaceuticals | Meals · 2025-08-28 | Leqvio | $18 |
| Amgen | Meals · 2025-08-25 | Repatha | $7 |
| Novartis Pharmaceuticals | Meals · 2025-08-22 | Leqvio | $21 |
| Novartis Pharmaceuticals | Meals · 2025-08-22 | Leqvio | $1 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Leqvio | $29 |
| Novartis Pharmaceuticals | Meals · 2025-08-19 | Leqvio | $29 |
| Novartis Pharmaceuticals | Meals · 2025-08-08 | Leqvio | $21 |
| Alnylam Pharmaceuticals | Meals · 2025-08-05 | Amvuttra | $25 |
| Novartis Pharmaceuticals | Meals · 2025-07-29 | Leqvio | $15 |
| Novartis Pharmaceuticals | Meals · 2025-07-29 | Leqvio | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-24 | Eliquis | $16 |
| Alnylam Pharmaceuticals | Meals · 2025-07-17 | Amvuttra | $24 |
| Novartis Pharmaceuticals | Meals · 2025-07-10 | Leqvio | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-25 | Camzyos | $20 |
| Amgen | Meals · 2025-06-03 | Repatha | $6 |
| Amgen | Meals · 2025-05-23 | Repatha | $7 |
| Novartis Pharmaceuticals | Meals · 2025-05-22 | Leqvio | $30 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-14 | Jardiance | $21 |
| Novartis Pharmaceuticals | Meals · 2025-04-18 | Leqvio | $19 |
| Alnylam Pharmaceuticals | Meals · 2025-04-17 | Amvuttra | $23 |
| Novartis Pharmaceuticals | Meals · 2025-04-02 | Leqvio | $19 |
| Novartis Pharmaceuticals | Meals · 2025-04-02 | Leqvio | $1 |
| Amgen | Meals · 2025-03-25 | Repatha | $6 |
| Regeneron Healthcare Solutions | Meals · 2025-03-19 | Evkeeza | $20 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Leqvio | $34 |
| Novartis Pharmaceuticals | Meals · 2025-03-13 | Leqvio | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-07 | Eliquis | $18 |
| Amgen | Meals · 2025-03-03 | Repatha | $9 |
| Novartis Pharmaceuticals | Meals · 2025-02-27 | Entresto | $27 |
| Novartis Pharmaceuticals | Meals · 2025-02-27 | Entresto | $0 |
| Amgen | Meals · 2025-02-27 | Repatha | $20 |
| Novartis Pharmaceuticals | Meals · 2025-02-20 | Leqvio | $30 |
| Novartis Pharmaceuticals | Meals · 2025-02-20 | Leqvio | $1 |
| Amgen | Meals · 2025-01-21 | Repatha | $6 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-15 | Jardiance | $30 |
| Amgen | Meals · 2025-01-13 | Repatha | $6 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $991
| Amgen | Repatha | $178 | 17 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $166 | 15 payments
|
| Novartis Pharmaceuticals | Leqvio | $158 | 11 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $131 | 6 payments
|
| Janssen Pharmaceuticals | Xarelto | $74 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Wainua | $65 | 3 payments
|
| Pfizer | Vyndaqel | $56 | 3 payments
|
| Lexicon Pharmaceuticals | None | $40 | 2 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $35 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $25 | 1 payment
|
| Boston Scientific | Bodyguardian | $22 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $21 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $20 | 1 payment
|
2023: $535
| Octapharma USA | Panzyga | $121 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $101 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $44 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $39 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $35 | 2 payments
|
| Scpharmaceuticals | Furoscix | $33 | 1 payment
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $29 | 2 payments
|
| Lexicon Pharmaceuticals | Inpefa | $29 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $27 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $22 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $21 | 1 payment
|
| HeartFlow | Ffrct | $20 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $13 | 1 payment
|
2022: $164
| Boston Scientific | General - Vascular Access | $49 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $45 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $39 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $31 | 1 payment
|
2020: $1,196
| Abbott Laboratories | Tricuspid Valve Repair System | $1,196 | 10 payments
|
2019: $3,089
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $3,089 | 19 payments
|
Professional record
- NPI
- 1316253024
- Licence
- CA A118294California A118294: Current · expires 2027-09-30
- Trained
- University of California, San Francisco School of Medicine, 2010
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X); Hospitalist (208M00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2010-08-19
- NPI last updated
- 2022-11-22
- NPI record certified
- 2022-11-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 354 Santa Fe Dr, Encinitas, CA, 92024 · 87 Encina Ave, Palo Alto, CA, 94301